Brief: Otsuka And Lundbeck Announce U.S. FDA Acceptance And Priority Review Of sNDA For Brexpiprazole For Treatment Of Agitation Associated With Alzheimer's Dementia
07/01/2023 14:45
Jan 7 (Reuters) - Otsuka Corp 4768.T :
* OTSUKA AND LUNDBECK ANNOUNCE U.S. FDA ACCEPTANCE AND
PRIORITY
REVIEW OF SNDA FOR BREXPIPRAZOLE FOR TREATMENT OF AGITATION
ASSOCIATED WITH ALZHEIMER'S DEMENTIA
Source text for Eikon: ID:nBwc24ww8a
Further company coverage: 4768.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options